Modeling uncertain outcomes of genetic testing: Factor v Leiden mutation and pregnant women

Genetics in Medicine

Volumn 15, Issue 5, 2013, Pages 335-337

  Grosse, Scott D ^a   Caughey, Aaron B ^b  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; MONTE CARLO METHOD; NOTE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PREDICTIVE VALUE; PREGNANCY OUTCOME; PREGNANT WOMAN; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; UNCERTAINTY; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

EID: 84877264329     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.17     Document Type: Note

References (16)

1. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
2. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93-104.
3. Goddard KA, Knaus WA, Whitlock E, et al. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med 2012;14:633-642.
4. Lazo-Langner A, Rodger MA, Barrowman NJ, Ramsay T, Wells PS, Coyle DA. Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis. BMC Med Res Methodol 2012;12:3.
5. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal riskbenefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010;12:686-693.
6. Prosser LA, Grosse SD, Kemper AR, Tarini BA, Perrin JM. Decision analysis, economic evaluation, and newborn screening: challenges and opportunities. Genet Med 2012; e-pub ahead of print 5 April 2012.
7. Little SE, Janakiraman V, Kaimal A, Musci T, Ecker J, Caughey AB. The costeffectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol 2010;202:253.e1-253.e7.
8. Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012;32:722-732.
9. Bajaj PS, Veenstra DL. A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med 2012; e-pub ahead of print 8 November 2012.
10. Bradley LA, Palomaki GE, Bienstock J, Varga E, Scott JA. Can Factor V Leiden and prothrombin G20210A testing in women with recurrent pregnancy loss result in improved pregnancy outcomes?: Results from a targeted evidence-based review. Genet Med 2012;14:39-50.
11. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003;1:433-438.
12. Tormene D, Grandone E, De Stefano V, et al. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low-molecularweight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thromb Haemost 2012;107:477-484.
13. Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol 2012;120:920-927.
14. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012;380:1741-1748.
15. Visser J, Ulander VM, Helmerhorst FM, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011;105:295-301.
16. Grosse SD. What is the value for money of prenatal carrier screening for spinal muscular atrophy? Too soon to say. Am J Obstet Gynecol 2010;202:209-211.